Variables clínicas en el diagnóstico y tratamiento del cáncer de próstata avanzado hormono sensible
DOI:
https://doi.org/10.48193/revistamexicanadeurologa.v82i2.700Palabras clave:
Cáncer de próstata avanzado hormonosensible, Enfermedad cN1, Cáncer de próstata oligometastásicoResumen
En los últimos años han surgido informes de los novedosos estudios de imagen para aumentar la sensibilidad para detectar enfermedad metastásica temprana y por lo mismo, el reconocimiento de subgrupos biológicos de hombres en el escenario del cáncer de próstata avanzado recién diagnosticado en relación al manejo del tumor primario para mejorar la supervivencia general de estos pacientes considerados a tener enfermedad sistémica y con solo tratamiento de supresión androgénica, fatal a corto o mediano plazo.
Referencias
Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, et al. Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(3):245–53. doi: https://doi.org/10.3322/caac.21391
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7–34. doi: https://doi.org/10.3322/caac.21551
.
Briganti A, Suardi N, Capogrosso P, Passoni N, Freschi M, di Trapani E, et al. Lymphatic spread of nodal metastases in high-risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum. The Prostate. 2012;72(2):186–92. doi: https://doi.org/10.1002/pros.21420
Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. doi: https://ascopubs.org/doi/10.1200/JCO.1995.13.1.8
Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. The Lancet. 2018;392(10162):2353–66. doi: https://doi.org/10.1016/S0140-6736(18)32486-3
Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019;75(3):410–8. doi: https://doi.org/10.1016/j.eururo.2018.09.008
Kyriakopoulos CE, Chen Y-H, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018;36(11):1080–7. doi: https://ascopubs.org/doi/10.1200/JCO.2017.75.3657
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. New England Journal of Medicine. 2017 Jul 27;377(4):352–60. doi: https://doi.org/10.1056/NEJMoa1704174
Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 Apr;77(4):508–47. doi: https://doi.org/10.1016/j.eururo.2020.01.012
Briganti A, Abdollah F, Nini A, Suardi N, Gallina A, Capitanio U, et al. Performance Characteristics of Computed Tomography in Detecting Lymph Node Metastases in Contemporary Patients with Prostate Cancer Treated with Extended Pelvic Lymph Node Dissection. European Urology. 2012;61(6):1132–8. doi: https://doi.org/10.1016/j.eururo.2011.11.008
Gabriele D, Collura D, Oderda M, Stura I, Fiorito C, Porpiglia F, et al. Is there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database. World J Urol. 2016;34(4):517–23. doi: https://link.springer.com/article/10.1007/s00345-015-1669-2
van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, et al. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int. 2017;119(2):209–15. doi: https://doi.org/10.1111/bju.13540
Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2020;77(4):403–17. doi: https://doi.org/10.1016/j.eururo.2019.01.049
Motterle G, Ahmed ME, Andrews JR, Karnes RJ. The Role of Radical Prostatectomy and Lymph Node Dissection in Clinically Node Positive Patients. Front Oncol. 2019;10(9):1395. doi: https://doi.org/10.3389/fonc.2019.01395
Gandaglia G, Soligo M, Battaglia A, Muilwijk T, Robesti D, Mazzone E, et al. Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. European Urology. 2019;75(5):817–25. doi: https://doi.org/10.1016/j.eururo.2018.10.042
Touijer KA, Karnes RJ, Passoni N, Sjoberg DD, Assel M, Fossati N, et al. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Eur Urol. 2018;73(6):890–6. doi: https://doi.org/10.1016/j.eururo.2017.09.027
Gupta M, Patel HD, Schwen ZR, Tran PT, Partin AW. Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit. BJU Int. 2019;123(2):252–60. doi: https://doi.org/10.1111/bju.14241
Ventimiglia E, Seisen T, Abdollah F, Briganti A, Fonteyne V, James N, et al. A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. European Urology Oncology. 2019;2(3):294–301. doi: https://doi.org/10.1016/j.euo.2019.02.001
Seisen T, Vetterlein MW, Karabon P, Jindal T, Sood A, Nocera L, et al. Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. Eur Urol. 2018;73(3):452–61. doi: https://doi.org/10.1016/j.eururo.2017.08.011
Zonana F, Sedano L, Ramírez Pérez E. Evaluación y opciones de tratamiento en pacientes con falla posterior a la prostatectomía por cáncer localizado de la próstata. Rev Mex Urol. 2011;71(2):111–27.
Zonana F, Sedano L , Ramírez Pérez E, Zarate Osorno A, García- Sáenz M, Lozano Zalce A. Radioterapia externa en el tratamiento del cáncer de la próstata: experiencia personal 1993-2015. Revista Mexicana de Urología. 2016 Sep 1;76(5):298-310. doi: https://doi.org/10.48193/revistamexicanadeurologa.v76i5.348
Ali SA, Hoyle A, James ND, Parker C, Brawley G, Attard H., et al. Benefit of prostate radiotherapy only or <4 bone metastasis and no visceral metastasis, exploratory analyses of metastatic site and number in the STAMPEDE “M’/RT comparison. Ann Oncol. 2019;30:V325.
Burdett S, Boevé LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, et al. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. European Urology. 2019;76(1):115–24. doi: https://doi.org/10.1016/j.eururo.2019.02.003
Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J, et al. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. Eur Urol. 2018;74(4):455–62. doi: https://doi.org/10.1016/j.eururo.2018.06.004
Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. The Lancet. 2019 May 18;393(10185):2051–8. doi: https://doi.org/10.1016/S0140-6736(18)32487-5
Patel PH, Chaw CL, Tree AC, Sharabiani M, van As NJ. Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer. World J Urol. 2019;37(12):2615–21. doi: https://doi.org/10.1007/s00345-019-02873-w
Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149–58. doi: https://doi.org/10.1016/S1470-2045(12)70560-0
Gravis G, Boher J-M, Chen Y-H, Liu G, Fizazi K, Carducci MA, et al. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. European Urology. 2018;73(6):847–55. doi: https://doi.org/10.1016/j.eururo.2018.02.001
Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019 Dec 1;30(12):1992–2003. doi: https://doi.org/10.1093/annonc/mdz396
Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. The Lancet Oncology. 2019;20(5):686–700. doi: https://doi.org/10.1016/S1470-2045(19)30082-8
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60. doi: https://doi.org/10.1016/S1470-2045(14)71205-7
Hoyle AP, Ali A, James ND, Cook A, Parker CC, de Bono JS, et al. Abiraterone in ‘High-’ and ‘Low-risk’ Metastatic Hormone-sensitive Prostate Cancer. Eur Urol. 2019 Dec;76(6):719–28. doi: https://doi.org/10.1016/j.eururo.2019.08.006
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019;381(2):121–31. doi: https://www.nejm.org/doi/10.1056/NEJMoa1903835
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019 Jul 4;381(1):13–24. doi: https://www.nejm.org/doi/10.1056/NEJMoa1903307
Publicado
Número
Sección
Licencia
Derechos de autor 2022 Revista Mexicana de Urología
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
